關鍵詞

突變 細胞 線粒體 免疫檢查點 中粒細胞 抗體 基因藥物

?

#今日行業(yè)熱點#

①Science：Oncogenic CDK13 mutations impede nuclear RNA surveillance

細胞周期蛋白依賴性激酶13（CDK13）突變通過抑制RNA監(jiān)測通路促進癌癥發(fā)生

DOI :10.1126/science.abn7625

②Advanced Drug Delivery Reviews：Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies

綜述：基于細胞的藥物載體及其臨床轉化的新進展、新技術和新策略

DOI :10.1016/j.addr.2023.114840

③Trends in Cancer：Fluorescence microscopic platforms imaging mitochondrial abnormalities in neurodegenerative diseases

神經退行性疾病中線粒體異常的熒光顯微鏡成像平臺

DOI :10.1016/j.addr.2023.114841

④Frontiers in Immunology：Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future

綜述：潛在靶點——針對抗中性粒細胞胞質抗體相關血管炎的免疫檢查點

DOI :10.3389/fimmu.2023.1156212

⑤Clinical Immunology：Blocking activation of CD4-CD8- T cells modulates their cytotoxic potential and decreases the expression of inflammatory and chemotactic receptors

阻斷CD4-CD8-T細胞的激活可調節(jié)其細胞毒活性并減少炎癥和趨化受體的表達

DOI :10.1016/j.clim.2023.109331

⑥Clinical Immunology：Crosstalk between microglia and neural stem cells influences the relapse of glioblastoma in GBM immunological microenvironment

在GBM免疫微環(huán)境中，小膠質細胞和神經干細胞之間的交互作用影響膠質母細胞瘤的復發(fā)

DOI :10.1016/j.clim.2023.109333

⑦創(chuàng)新CD47抗體來佐利單抗用于血液系統(tǒng)惡性腫瘤MDS（骨髓增生異常綜合征）的中國Ⅲ期注冊臨床試驗已完成首例患者給藥

⑧國內首個獲批進入臨床試驗的血友病B的腺相關病毒（AAV）基因藥物BBM-H901順利完成Ⅲ期注冊臨床試驗受試者給藥

⑨在研乙肝新藥反義寡核苷酸（ASO）bepirovirsen（GSK3228836）在中國啟動Ⅲ期臨床

⑩用于甲型流感的ZSP1273片Ⅲ期臨床研究已完成全部病例數(shù)入組

科學探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！